P-BCMA-ALLO1

N/A

Report date: 2024/04/26 20:00:28

Base Information

Drug NameP-BCMA-ALLO1
Drug Alias NameP-BCMA-ALLO1RG-6538
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTransposagen Biopharmaceuticals IncJanssen Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesPoseida Therapeutics IncGenentech Inc
Inactive CompaniesJanssen Biotech Inc
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A